

The endocannabinoid system a potential buffer against SUD development following trauma exposure

Leah Mayo, PhD


Parker Research Chair in Psychedelics

Mathison Centre for Mental Health Research and Education

Hotchkiss Brain Institute

Department of Psychiatry

University of Calgary



CSAN
Center for Social and
Affective Neuroscience



THE MATHISON CENTRE
for MENTAL HEALTH RESEARCH & EDUCATION



HOTCHKISS
BRAIN INSTITUTE



UNIVERSITY OF
CALGARY

Email: leah.mayo@ucalgary.ca




@MayoOnTheBrain

Disclosures

C.A.N

The Central Association for Alcohol and Narcotics Information,
CAN



Ongoing investigator-initiated clinical trial with Janssen Pharmaceuticals

Does exposure **childhood maltreatment (trauma)** increase the risk for **SUD** in adulthood?

Linköping Child and Adolescent Psychiatry - Trauma Unit (est. 1980's)

Regional and National Patient registers


Health care visits (substance dependence clinic)

Swedish Multi-Generational register

Parents, half/full siblings, cousins






3-fold increased risk for SUD
Even when controlling for:
recall bias, familial confounding






Childhood maltreatment	692	691	421	152	0	0	0
Clinical controls	1970	1964	168	634	0	0	0
Population controls	25863	24919	20634	11225	4286	989	42

How does **childhood trauma** contribute to **SUD** development in adulthood?

STRESS



How does **childhood trauma** contribute to **SUD** development in adulthood?



How does **childhood trauma** contribute to **SUD** development in adulthood?

Session 1: Clinical Assessment

Clinical interview

Self-report questionnaires

Session 2: Behavioral Testing

Stress reactivity

Affective processing

Fear learning

Session 3: Neuroimaging

Emotion conflict

Threat processing

Resting state, DTI, ASL



Irene Perini

 @NeuroIP

CHILDHOOD TRAUMA

YES

NO


YES

SUBSTANCE USE
DISORDER (SUD)


NO

Trauma+SUD (N = 26)	SUD only (N = 25)
Trauma only (N = 26)	Control (N = 24)

SUD development is associated with greater clinical symptoms than childhood trauma alone






Group $p = 0.012$; SUD $p = 0.016$, CM $p = 0.090$
Trauma + SUD vs control $p = 0.026$, SUD vs control $p = 0.025$;
Trauma only vs control $p = 0.097$




Group $p = 0.012$; SUD $p = 0.008$, SUD x CM $p = 0.050$
Trauma + SUD vs control $p = 0.013$, SUD vs control $p = 0.010$;
Trauma only vs control $p = 0.058$

Resilience after childhood trauma is associated with elevated AEA





Resilience after **childhood trauma** is associated with elevated AEA during stress exposure





Effect of time $p = 0.025$; CM x SUD x Time $p = 0.016$

CM vs control $p = 0.007$




Cortisol: Effect of time: $p < 0.001$; group $p = 0.63$; group x time $p = 0.67$

Resilience after **childhood trauma** is associated with attenuated reactivity to negative affective stimuli



Group p = 0.96; group x stimulus p = 0.38





- Control
- Trauma only
- Trauma+SUD
- SUD only




Group x stimulus p = 0.006
Trauma only v control p = 0.036

Perini*, Mayo* (in revision)

Resilience after childhood trauma is associated with greater activation of emotion regulation & salience processing regions



Etkin et al., 2006 *Neuron*




Irene Perini
@NeuroIP

Trauma "Vulnerable"

(Trauma + SUD)


Trauma "Resilient"

(Trauma only)





Elevating AEA via FAAH inhibition in PTSD




Primary Outcome: CAPS-5 scores

Self-report: PTSD symptoms (PCL-5), sleep (PSQI), anxiety (STAI), mood (POMS) + blood samples


FAAH inhibition in PTSD

Fear-potentiated startle




FAAH inhibition in healthy adults


Mayo et al., 2020 *Biological Psychiatry*






Greater recall of fear extinction (24hrs later)




Stress Reactivity



Reduced subjective and autonomic stress reactivity




Attenuated stress-induced negative affect



FAAH inhibition in PTSD

Fear-potentiated startle




FAAH inhibition in healthy adults

Mayo et al., 2020 *Biological Psychiatry*


Greater recall of fear extinction (24hrs later)

Stress Reactivity







Reduced subjective and autonomic stress reactivity

Facial EMG




Attenuated stress-induced negative affect

FAAH inhibition in PTSD



Fonzo et al., 2017 *Am J Psychiatry*

Elevating AEA via FAAH inhibition in PTSD





Primary Outcome: CAPS-5 scores



Self-report: PTSD symptoms (PCL-5), sleep (PSQI), anxiety (STAI), mood (POMS) + blood samples

FAAH inhibition in PTSD

Fear-potentiated startle




FAAH inhibition in PTSD



Prolonged Exposure for PTSD



Gerhard Andersson
Linköping University



8-week PE treatment
1 module per week

Modules 3-6: *in vivo* and imaginal exposure

The screenshot shows the 'PAPE studien' website. The menu includes 'Start' and 'Meny'. The course modules are listed as follows:

1. Introduktion
2. Förberedande arbete inför exponering
3. In vivo-expon

Below the list are icons representing a person walking, a person with a heart, and a person with a question mark.


Elevating AEA via FAAH inhibition in PTSD



Start date: Nov 2020

Target Enrollment: N = 90


Current Status: N = 75



Primary Outcome: CAPS-5 scores

Self-report: PTSD symptoms (PCL-5), sleep (PSQI), anxiety (STAI), mood (POMS) + blood samples

Summary & Conclusions



What we [think we] know

Elevated **AEA**
may *protect*
against **SUD**
development
following
childhood trauma
exposure

Center for Social & Affective Neuroscience

Markus Heilig



Andrea Capusan

Irene Perini



Elisabeth Paul

Åsa Axén



Per Gustafsson

Linköping University

Gerhard Andersson

Niclas Stensson

University of Calgary

Matt Hill



@MayoOnTheBrain

Email: leah.mayo@ucalgary.ca

The Psychedelic and Cannabinoid Therapeutics (PaCT) Lab

Madeleine Jones (LiU)

Hilda Engelbrektsson (LiU)


Raegan Mazurka (Dalhousie Univ)

Connor Haggarty (Univ of Chicago)

Anisja Hühne (LMU Munich)



@MayoBrainLab



Svenska
Läkaresällskapet



Vetenskapsrådet



UNIVERSITY OF
CALGARY



Awarding **NARSAD** Grants